Home > Riviste > Minerva Pediatrics > Fascicoli precedenti > Minerva Pediatrica 2018 December;70(6) > Minerva Pediatrica 2018 December;70(6):513-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Pediatrica 2018 December;70(6):513-8

DOI: 10.23736/S0026-4946.16.04630-2

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Prevention of syncytial respiratory virus infection with palivizumab: descriptive and comparative analysis after 12 years of use

Eduardo NARBONA-LOPEZ 1, José UBEROS 1 , Ana CHECA-ROS 1, Rocio RODRIGUEZ-BELMONTE 2, Antonio MUÑOZ-HOYOS 1

1 Unit of Clinical Pediatrics, San Cecilio University Hospital, Granada, Spain; 2 St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, UK



BACKGROUND: The use of palivizumab has been recommended to prevent syncytial respiratory virus (SRV) infection in vulnerable children.
METHODS: We performed a retrospective study of hospital admissions for bronchiolitis from 2000 to 2012 in the context of a prevention study with palivizumab in at-risk newborns.
RESULTS: A total of 952 children (59.5% males) were admitted due to bronchiolitis. Admissions occurred in younger children in the SRV+ cases compared to the SRV- cases (P<0.001). Additionally, 641 children were treated with Palivizumab at our service. Sixty of these children (9.8%) were admitted due to bronchiolitis and SRV was detected in 22 of them (3.4%). Fifty (7.8%) had underlying diseases, 6 (0.9%) presented with a history of perinatal infection and 20 (3.12%) had been part of a multiple birth. The treated children with some additional risk factor presented a greater risk of admission due to bronchiolitis (OR=1.99, P=0.045); however, this was not observed for admissions due to SRV (P=0.945).
CONCLUSIONS: Children treated with Palivizumab showed a lower rate of SRV infection, despite having more risk factors associated with a higher risk of infection or complications.


KEY WORDS: Palivizumab - Respiratory syncytial virus infections - Child - Prevention and control - Antibiotic prophylaxis - Bronchiolitis

inizio pagina